Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart transplant patients get hepatitis c cure hope

NCT ID NCT03886077

Disease control Sponsor: Sentara Norfolk General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a 12-week course of glecaprevir/pibrentasivir can safely cure hepatitis C in heart transplant patients who got the virus from infected donors. Fifty adults on the transplant waitlist were enrolled, and those who received a hepatitis C-positive heart were treated after infection was confirmed. The main goal was to see if the virus stayed gone 12 weeks after treatment, with a secondary check on heart artery health one year later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glecaprevir/pibrentasivir
What this could lead to
If successful, this could show that treating hepatitis C after heart transplant is safe and effective, potentially improving outcomes for patients who receive infected donor hearts.
What could go wrong
This is a small, early study with only 50 participants and no blinding, so results may not apply to everyone. The long-term effects on heart health are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Mar 2019

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

50 subjects listed for cardiac transplantation will be enrolled. Patients will be educated about this protocol prior to transplant, and informed consent obtained. Enrolled subjects who receive a transplant with a NAT positive HCV infected donor will undergo NAT testing and surveillance post-operatively. In addition, patients who are offered an HCV infectious organ will be "re-consented" at the time of transplantation admission.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must meet all of the inclusion criteria specified below in order to be eligible for participation in this study 1. Willing and capable of providing written informed consent 2. Age ≥18 years 3. On UNOS list as a candidate for heart transplant Exclusion Criteria: * Subjects who meet any of the following exclusion criteria cannot be enrolled in this study. 1. Individuals under 18 years of age 2. History of advanced liver disease, including active hepatitis B or C, detectable hepatitis B surface Ag, hepatitis B DNA, HCV RNA, or cirrhosis 3. Pregnant individuals 4. HIV antibody positive

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Morality

Contacts and locations

Locations

  • Sentara Norfolk General Hospital

    Norfolk, Virginia, 23507, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.